Ischemic hepatitis

Revision as of 11:15, 7 July 2024 by Rithish Nimmagadda (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

WikiDoc Resources for Ischemic hepatitis

Articles

Most recent articles on Ischemic hepatitis

Most cited articles on Ischemic hepatitis

Review articles on Ischemic hepatitis

Articles on Ischemic hepatitis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ischemic hepatitis

Images of Ischemic hepatitis

Photos of Ischemic hepatitis

Podcasts & MP3s on Ischemic hepatitis

Videos on Ischemic hepatitis

Evidence Based Medicine

Cochrane Collaboration on Ischemic hepatitis

Bandolier on Ischemic hepatitis

TRIP on Ischemic hepatitis

Clinical Trials

Ongoing Trials on Ischemic hepatitis at Clinical Trials.gov

Trial results on Ischemic hepatitis

Clinical Trials on Ischemic hepatitis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ischemic hepatitis

NICE Guidance on Ischemic hepatitis

NHS PRODIGY Guidance

FDA on Ischemic hepatitis

CDC on Ischemic hepatitis

Books

Books on Ischemic hepatitis

News

Ischemic hepatitis in the news

Be alerted to news on Ischemic hepatitis

News trends on Ischemic hepatitis

Commentary

Blogs on Ischemic hepatitis

Definitions

Definitions of Ischemic hepatitis

Patient Resources / Community

Patient resources on Ischemic hepatitis

Discussion groups on Ischemic hepatitis

Patient Handouts on Ischemic hepatitis

Directions to Hospitals Treating Ischemic hepatitis

Risk calculators and risk factors for Ischemic hepatitis

Healthcare Provider Resources

Symptoms of Ischemic hepatitis

Causes & Risk Factors for Ischemic hepatitis

Diagnostic studies for Ischemic hepatitis

Treatment of Ischemic hepatitis

Continuing Medical Education (CME)

CME Programs on Ischemic hepatitis

International

Ischemic hepatitis en Espanol

Ischemic hepatitis en Francais

Business

Ischemic hepatitis in the Marketplace

Patents on Ischemic hepatitis

Experimental / Informatics

List of terms related to Ischemic hepatitis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  ; Rithish Nimmagadda,MBBS.[2]

Overview

Ischemic hepatitis (also known as shock liver) is a condition of decreased blood supply to the liver resulting in injury to liver cells (hepatocytes), which occurs in a diffuse fashion.

The decreased blood flow (perfusion) to the liver is usually due to shock or low blood pressure. However, local causes involving the hepatic artery that supplies oxygen to the liver, such as sickle cell crisis and thrombosis of the hepatic artery, can also cause ischemic hepatitis. Patients with ischemic hepatitis are usually very ill.

Blood testing usually shows high levels of the liver transaminase enzymes, AST and ALT, which may exceed 1000 U/L. People who develop ischemic hepatitis may have pain in the right upper part of the abdomen, but they usually feel more unwell because of the serious reason that they developed the ischemia, than due to the ischemic hepatitis itself. Jaundice can occur, but is rare and transient, as is actual loss of function of the liver.

Ischemic hepatitis is related to another condition called congestive hepatopathy or nutmeg liver, which is a backflow condition due to poor drainage of the liver, usually due to heart failure. As a result, the two entities can co-exist.

Historical Perspective

The most frequent cause of severe acute liver damage in the US is ischemic hepatitis, which affects around 2% of patients hospitalized to the intensive care unit. About 80% of patients had an underlying cardiac condition.

Pathophysiology

The pathophysiology of hypoxia and necrosis in hepatic tissue:

1-Congestion in the liver brought on by an underlying illness (heart failure, for example) can lead to anatomical alterations in the liver (hepatocyte atrophy, sinusoidal centrilobular dilatation, etc.) and altered hepatic blood flow.

2-Hepatic blood flow is affected by reduced cardiac output, hypovolemic shock, or cardiac arrest.

3-Septic shock is caused by the following factors: circulating endotoxins, inflammatory cytokines, hepatic metabolic demands, hepatocytes' capability to collect and use oxygen, and hepatic blood flow.


clinical features

Symptomless Weakness, exhaustion, and changed mental state hypertension and bradycardia Hepatomegaly, right upper quadrant pain, nausea, vomiting, and anorexia

Diagnosis

clinical history and physical examination - cardiopulmonary disease, hypotension

-lab investigations

AST levels that are extremely high (> 1000 U/L) Levels of serum peak 1-3 days Values stabilize about 7–10 days after the restoration of hepatic perfusion. elevated levels of bilirubin increased LDH concentrations ALT:LDH ratio less than 1.5 elevated BUN and creatinine levels in the blood Normal levels of alkaline phosphatase

Studies on coagulation: prothrombin time may be extended

Imaging: to detect portal vein thrombosis or hepatic artery blockage (e.g., using Doppler ultrasonography, MRI, or arteriography) Other: to rule out other potential causes of acute liver damage, such as acute viral hepatitis or acetaminophen overdose.

Differential Diagnosis

1.Drug induced acute liver failure 2.Acute viral hepatitis 3.Hepatic infarction


Treatment

Medical Therapy

Ischemic hepatitis does not have a particular therapy. Address the root cause. Hemodynamic assistance (vasopressor, inotropes, volume resuscitation) and restoration of cardiac output are required.

Prognosis

Depends on the underlying condition, duration, and extent of the hemodynamic compromise

Higher death rates are linked to the following factors: patient on Vasopressor therapy high INR septic shock failure of the kidneys

References

Template:WH Template:WS